Kenneth Hoberman
2019
In 2019, Kenneth Hoberman earned a total compensation of $2.5M as Chief Operating Officer at Stemline Therapeutics, a 67% decrease compared to previous year.
Compensation breakdown
| Bonus | $279,333 |
|---|---|
| Salary | $517,283 |
| Stock Awards | $1,660,733 |
| Total | $2,457,349 |
Hoberman received $1.7M in stock awards, accounting for 68% of the total pay in 2019.
Hoberman also received $279.3K in bonus and $517.3K in salary.
Rankings
In 2019, Kenneth Hoberman's compensation ranked 4,941st out of 13,971 executives tracked by ExecPay. In other words, Hoberman earned more than 64.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,941 out of 13,971 | 65th |
Division Manufacturing | 1,840 out of 5,701 | 68th |
Major group Chemicals And Allied Products | 648 out of 2,200 | 71st |
Industry group Drugs | 547 out of 1,886 | 71st |
Industry Pharmaceutical Preparations | 410 out of 1,398 | 71st |
Source: SEC filing on April 29, 2020.
Hoberman's colleagues
We found three more compensation records of executives who worked with Kenneth Hoberman at Stemline Therapeutics in 2019.